Live Analyst Rating Changes 1526 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/John Newman
CG
John Newman
Canaccord Genuity
Wall Street Analyst
★☆☆☆☆
#2515
on 13Foresight · ranked by our own returns
33%
Success Rate
-12.3%
Average Return
17 of 51 calls profitable · -2424.1% vs benchmark
📈 Across the calls we could measure, roughly 33% of John Newman's ratings turned a profit when each position was held for 1 year — averaging -12.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

142 Buy 8 Hold 0 Sell
John's Stock Coverage 50 ratings · 2026-06-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
TYRA
Tyra Bioscience
 Jun 18, 2026 BUY Strong Buy
+57.9% avg upside
17 analysts
$50.00
76.63% Upside
 ·
DCTH
Delcath Systems
 Jun 17, 2026 BUY Strong Buy
+90.3% avg upside
11 analysts
$21.00
79.64% Upside
 +0.0%
TNGX
Tango Therapeutics
 Jun 11, 2026 BUY Strong Buy
+24.3% avg upside
14 analysts
$42.00
50.21% Upside
 +8.3%
NUVL
Nuvalent
 Jun 10, 2026 HOLD Buy
-0.3% avg upside
21 analysts
$126.00
2.01% Upside
 +0.0%
BBOT
BridgeBio Oncology Therapeutics
 Jun 08, 2026 BUY Strong Buy
+232.1% avg upside
10 analysts
$23.00
204.26% Upside
 -1.4%
BNTX
BioNTech SE
 Jun 01, 2026 BUY Strong Buy
+50.5% avg upside
26 analysts
$158.00
73.82% Upside
 -0.9%
CMPX
Compass Therapeutics
 May 22, 2026 BUY Strong Buy
+373.4% avg upside
19 analysts
$7.00
246.56% Upside
 +0.9%
REGN
Regeneron
 May 19, 2026 BUY Strong Buy
+26.9% avg upside
57 analysts
$875.00
43.51% Upside
 -3.4%
MRKR
Marker Therapeutics
 May 19, 2026 BUY Strong Buy
+994.4% avg upside
9 analysts
$8.00
501.49% Upside
 ·
CADL
Candel Therapeutics
 May 18, 2026 BUY Strong Buy
+112.6% avg upside
10 analysts
$25.00
200.83% Upside
 +10.4%
ALLO
Allogene Therapeutics
 May 14, 2026 BUY Strong Buy
+662.1% avg upside
28 analysts
$14.00
600.10% Upside
 -11.2%
ACET
Adicet Bio
 May 14, 2026 BUY Strong Buy
+212.8% avg upside
14 analysts
$18.00
122.19% Upside
 -3.0%
ATRA
Atara Biotherapeutics
 May 13, 2026 BUY Buy
+79.6% avg upside
18 analysts
$13.00
29.11% Upside
 -7.7%
LCTX
Lineage Therap
 May 13, 2026 BUY Strong Buy
+342.7% avg upside
16 analysts
$9.00
643.89% Upside
 -5.5%
MCRB
Seres Therapeutics
 May 06, 2026 BUY Buy
+162.2% avg upside
10 analysts
$22.00
232.91% Upside
 -5.1%
XNCR
Xencor
 May 06, 2026 BUY Buy
+159.9% avg upside
27 analysts
$38.00
200.56% Upside
 -13.4%
IRD
Opus Genetics
 Nov 12, 2024 BUY Strong Buy
+154.5% avg upside
23 analysts
$10.00
145.74% Upside
 +60.0%
ONCY
Oncolytics Biotech
 Nov 12, 2024 BUY Strong Buy
+652.6% avg upside
12 analysts
$5.00
420.90% Upside
 +1.8%
PTN
Palatin Technologies
 Oct 01, 2024 BUY Strong Buy
+899.8% avg upside
4 analysts
$300.00
2459.78% Upside
 -82.2%
RNAC
Cartesian Therapeutics
 Aug 08, 2024 BUY Strong Buy
+228.2% avg upside
19 analysts
$43.00
346.50% Upside
 -18.2%
TSE:APS
Aptose Biosciences
 May 15, 2024 BUY Strong Buy
+4065.6% avg upside
10 analysts
$254.94
11358.10% Upside
 ·
AGIO
Agios Pharma
 Feb 16, 2022 BUY Strong Buy
+73.2% avg upside
29 analysts
$44.00
28.73% Upside
 -12.7%
CARM
Carisma Therapeutics
 Aug 17, 2021 BUY Buy
+15294.7% avg upside
11 analysts
$3.00
15689.56% Upside
 ·
HK:0013
HUTCHMED (China)
May 26, 2021 BUY Buy
+619.1% avg upside
6 analysts
$352.60
2047.35% Upside
 ·
BDSX
Biodesix
 May 12, 2021 BUY Strong Buy
+92.3% avg upside
8 analysts
$31.00
84.41% Upside
 -87.7%
KLDO
Kaleido Biosciences
 May 04, 2021 BUY Buy
+13249900.0% avg upside
5 analysts
$19.00
18999899.93% Upside
 -98.9%
HCM
HUTCHMED
 May 03, 2021 BUY Strong Buy
+208.7% avg upside
9 analysts
$45.00
337.73% Upside
 -53.4%
RNTX
Rein Therapeutics
 Mar 25, 2021 BUY Strong Buy
+1064.9% avg upside
5 analysts
$5.00
445.98% Upside
 -61.5%
TSE:PRN
Profound Medical
 Mar 09, 2020 BUY Strong Buy
+96.8% avg upside
11 analysts
$14.16
47.51% Upside
 ·
ALDX
Aldeyra Therapeutics
 Jun 26, 2019 BUY Strong Buy
+713.6% avg upside
21 analysts
$20.00
920.37% Upside
 -31.0%
MTVA
MetaVia
 Aug 13, 2018 BUY Strong Buy
+1769.3% avg upside
13 analysts
$6.00
274.92% Upside
 -61.5%
XENE
Xenon
 Jun 27, 2017 BUY Strong Buy
+19.0% avg upside
28 analysts
$5.00
90.45% Downside
 ·
AUPH
Aurinia Pharmaceuticals
 Mar 10, 2017 BUY Strong Buy
-7.2% avg upside
12 analysts
$10.00
39.25% Downside
 -34.8%
CBIO
Crescent Biopharma
 Mar 01, 2017 BUY Strong Buy
+26.9% avg upside
17 analysts
$12.00
32.22% Downside
 ·
IMUX
Immunic
 Dec 30, 2016 BUY Strong Buy
+166.0% avg upside
21 analysts
$10.00
29.57% Downside
 +36.8%
DARE
Daré Bioscience
 Nov 09, 2016 BUY Strong Buy
+516.8% avg upside
14 analysts
$60.00
2665.03% Upside
 -65.2%
LPCN
Lipocine
 Oct 11, 2016 BUY Strong Buy
+672.5% avg upside
4 analysts
$15.00
543.84% Upside
 -19.7%
ZVRA
Zevra Therapeutics
 Aug 10, 2016 BUY Strong Buy
+85.3% avg upside
15 analysts
$34.00
163.52% Upside
 -20.6%
SVRA
Savara
 Jul 26, 2016 BUY Strong Buy
+57.8% avg upside
17 analysts
$3.00
45.41% Downside
 -32.4%
GEO
Geo Group
 Jun 13, 2016 HOLD Strong Buy
+22.1% avg upside
11 analysts
$90.00
207.30% Upside
 +54.8%
RCKT
Rocket Pharmaceuticals
 May 13, 2016 BUY Buy
+393.7% avg upside
29 analysts
$30.00
795.57% Upside
 -81.8%
ZG
Zillow Group Class A
 May 02, 2016 BUY Buy
+95.2% avg upside
45 analysts
$26.00
19.96% Downside
 +51.2%
MU
Micron
 Mar 31, 2016 BUY Strong Buy
-36.2% avg upside
52 analysts
$18.00
98.46% Downside
 +176.0%
TLPH
Talphera
 Mar 09, 2015 HOLD Buy
+332.4% avg upside
15 analysts
$6.00
450.38% Upside
 -34.7%
JAZZ
Jazz Pharmaceuticals
 Mar 03, 2015 BUY Strong Buy
-1.8% avg upside
35 analysts
$201.00
10.55% Downside
 -28.8%
RMTI
Rockwell Med
 Jan 07, 2015 BUY Buy
+1445.2% avg upside
11 analysts
$24.00
3649.99% Upside
 -20.8%
ARCT
Arcturus Therapeutics
 Oct 07, 2014 HOLD Buy
+290.9% avg upside
35 analysts
$9.00
19.50% Upside
 -9.2%
BIIB
Biogen
 Dec 20, 2011 BUY Strong Buy
+25.1% avg upside
51 analysts
$127.00
35.50% Downside
 +36.6%
MNKD
MannKind
 Mar 15, 2010 SELL Buy
+78.6% avg upside
22 analysts
$5.00
26.97% Upside
 +52.0%
BC
Brunswick
 Jun 10, 2009 SELL Buy
-2.8% avg upside
32 analysts
 — -273.8%
🔒 45 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
John Newman — Frequently Asked Questions
How accurate are John Newman's stock ratings?
Based on the calls 13Foresight could measure, about 33% of John's ratings were profitable over a one-year hold, with an average return of -12.3% per rating, or -2424.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is John ranked on 13Foresight?
John Newman is currently ranked #2515 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does John cover?
John most recently has ratings on TYRA, DCTH, TNGX, NUVL, BBOT, BNTX, CMPX, REGN, MRKR, CADL, ALLO, ACET and 38 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.